Gritman Medical Center INC
Gritman Medical Center INC was paid $3.73M by Medicaid between Jan 2018 and Nov 2024, across 117 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoGRITMAN MEDICAL CENTER INC
MOSCOW, ID 83843
MOSCOW, ID 83843
33aNPI1619988144assigned 08/10/2006
33bProvider typeDiabetes Educator Registered Nurse
28Total paid$3.73M
24GClaims93,535
24DCodes billed117
24AFirst – last monthJan 2018 – Nov 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,374 | $1.26M | |
| 2019 | 28,474 | $1.22M | |
| 2020 | 16,096 | $629K | |
| 2021 | 7,328 | $199K | |
| 2022 | 8,157 | $216K | |
| 2023 | 6,469 | $144K | |
| 2024incomplete | 2,637 | $61K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 4,834 | 4,197 | $825K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 14% | 6,383 | 5,730 | $537K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 3,251 | 2,551 | $460K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 7.6% | 3,977 | 1,182 | $283K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.9% | 1,032 | 760 | $184K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 4.0% | 1,737 | 1,554 | $149K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 3.7% | 2,737 | 1,036 | $138K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.8% | 2,105 | 1,726 | $104K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.8% | 3,269 | 1,363 | $104K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.7% | 787 | 482 | $101K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.7% | 2,354 | 935 | $101K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.9% | 291 | 233 | $70K |
105 more codes
| 94761 | 1.7% | 1,111 | $64K | |
| 80053 | Comprehensive metabolic panel | 1.4% | 7,498 | $52K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,960 | $36K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 997 | $29K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,173 | $28K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,062 | $27K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 422 | $27K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 178 | $26K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,055 | $22K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 27 | $22K |
| 93041 | <1% | 692 | $18K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,285 | $17K |
| 84145 | <1% | 1,011 | $17K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 597 | $15K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 896 | $15K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 274 | $14K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 805 | $14K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 213 | $12K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 232 | $12K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 158 | $11K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 844 | $11K |
| 84484 | <1% | 1,150 | $11K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 734 | $10K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 802 | $9K |
| 81001 | <1% | 2,913 | $9K | |
| 87088 | <1% | 1,291 | $8K | |
| 86140 | <1% | 1,526 | $8K | |
| 83880 | <1% | 437 | $7K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 202 | $6K |
| 83735 | <1% | 1,209 | $6K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 104 | $5K |
| 80061 | Lipid panel | <1% | 636 | $5K |
| 87077 | <1% | 1,131 | $5K | |
| 85610 | <1% | 985 | $5K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 108 | $5K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 148 | $4K |
| 80306 | <1% | 377 | $4K | |
| 83690 | <1% | 686 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 758 | $4K |
| 87186 | <1% | 799 | $4K | |
| 71045 | Radiologic examination, chest; single view | <1% | 868 | $4K |
| 87040 | <1% | 351 | $3K | |
| 83605 | <1% | 292 | $3K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 384 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 100 | $3K |
| 84439 | <1% | 386 | $3K | |
| 82550 | <1% | 284 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 446 | $3K |
| 84703 | <1% | 358 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 353 | $3K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 113 | $2K |
| 87081 | <1% | 366 | $2K | |
| 85027 | <1% | 344 | $2K | |
| 97113 | <1% | 48 | $2K | |
| 82150 | <1% | 242 | $2K | |
| 82962 | <1% | 291 | $2K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $2K |
| 85652 | <1% | 338 | $2K | |
| 85379 | <1% | 92 | $1K | |
| 76830 | Ultrasound, transvaginal | <1% | 21 | $1K |
| 87070 | <1% | 142 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 96 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 191 | $1K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 87 | $984.49 |
| 87420 | <1% | 80 | $959.93 | |
| 94760 | <1% | 20 | $895.68 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 25 | $865.54 |
| 81025 | <1% | 135 | $864.64 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 25 | $864.22 |
| 86850 | <1% | 139 | $833.70 | |
| 73630 | <1% | 52 | $762.35 | |
| 94664 | <1% | 27 | $751.38 | |
| 97161 | <1% | 14 | $741.95 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 29 | $739.05 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 28 | $730.76 |
| 97162 | <1% | 12 | $619.72 | |
| 0002A | <1% | 16 | $600.00 | |
| 0001A | <1% | 13 | $520.00 | |
| 86900 | <1% | 131 | $508.43 | |
| 0011A | <1% | 15 | $480.00 | |
| 0012A | <1% | 15 | $440.00 | |
| 86901 | <1% | 131 | $415.25 | |
| 85730 | <1% | 40 | $297.62 | |
| 85007 | <1% | 68 | $266.01 | |
| 73110 | <1% | 14 | $236.50 | |
| 82570 | <1% | 61 | $223.44 | |
| 73610 | <1% | 14 | $191.14 | |
| 82607 | <1% | 13 | $183.60 | |
| 76857 | <1% | 15 | $175.14 | |
| 99001 | <1% | 115 | $150.00 | |
| 80320 | <1% | 347 | $88.11 | |
| 81000 | <1% | 27 | $38.58 | |
| 84100 | <1% | 17 | $26.38 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 81 | $5.01 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 74 | $2.03 |
| A9270 | Non-covered item or service | <1% | 1,032 | $1.67 |
| 96376 | 0% | 28 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 52 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 15 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 28 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 37 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 19 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 13 | $0.00 |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 0% | 33 | $0.00 |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 0% | 37 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBESST, KARA (PRESIDENT/ CEO)
| Provider | Location | Paid |
|---|---|---|
| Gritman Medical Center INC | Potlatch, ID | $151K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.